TABLE 1.
Baseline pathogen and agent (no. of pathogens tested) | MIC (mg/liter) |
||
---|---|---|---|
Range | MIC50 | MIC90 | |
Enterobacteriaceae | |||
All Enterobacteriaceae (803) | |||
Ceftazidime-avibactam | ≤0.008 to >256 | 0.12 | 0.25 |
Ceftazidime | ≤0.03 to >64 | 0.12 | 32 |
Amikacin | 0.5 to >64 | 2 | 4 |
Aztreonam | ≤0.03 to >64 | 0.06 | 64 |
Cefepime | ≤0.008 to >16 | 0.03 | >16 |
Ceftaroline | ≤0.008 to >256 | 0.12 | >256 |
Ceftriaxone | ≤0.015 to >32 | 0.06 | >32 |
Gentamicin | ≤0.12 to >16 | 0.5 | >16 |
Imipenem | 0.06 to 16 | 0.12 | 0.5 |
Levofloxacin | 0.008 to >8 | 0.06 | >8 |
Meropenem | 0.008 to >8 | 0.015 | 0.06 |
Piperacillin-tazobactam | ≤0.06 to >128 | 2 | 16 |
Tigecycline | 0.06 to 9 | 0.25 | 1 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | >8 |
Citrobacter freundii complex (32) | |||
Ceftazidime-avibactam | 0.03 to 0.5 | 0.12 | 0.25 |
Ceftazidime | 0.12 to >64 | 0.25 | 2 |
Amikacin | 0.5 to 4 | 1 | 2 |
Aztreonam | ≤0.03 to >64 | 0.12 | 16 |
Cefepime | 0.015 to >16 | 0.03 | 1 |
Ceftaroline | 0.06 to >256 | 0.12 | 128 |
Ceftriaxone | 0.03 to >32 | 0.12 | >32 |
Gentamicin | 0.25 to >16 | 0.5 | 0.5 |
Imipenem | 0.12 to 1 | 0.25 | 0.5 |
Levofloxacin | 0.015 to 8 | 0.06 | 0.5 |
Meropenem | 0.008 to 0.06 | 0.015 | 0.03 |
Piperacillin-tazobactam | 0.5 to >128 | 2 | 128 |
Tigecycline | 0.12 to 2 | 0.25 | 0.5 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | ≤0.25 |
Enterobacter aerogenes (10) | |||
Ceftazidime-avibactam | 0.12 to 2 | 0.12 | 0.5 |
Ceftazidime | 0.12 to >64 | 0.12 | 0.5 |
Amikacin | 1 to >64 | 1 | 2 |
Aztreonam | ≤0.03 to >64 | ≤0.03 | 0.25 |
Cefepime | 0.03 to >16 | 0.03 | 0.06 |
Ceftaroline | 0.06 to >256 | 0.12 | 0.25 |
Ceftriaxone | 0.06 to >32 | 0.06 | 0.25 |
Gentamicin | 0.25 to >16 | 0.5 | 0.5 |
Imipenem | 0.12 to 1 | 0.5 | 1 |
Levofloxacin | 0.03 to 0.12 | 0.06 | 0.12 |
Meropenem | 0.015 to 0.06 | 0.03 | 0.03 |
Piperacillin-tazobactam | 1 to >128 | 4 | 4 |
Tigecycline | 0.25 to 1 | 0.5 | 0.5 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | 0.5 |
Enterobacter cloacae (29) | |||
Ceftazidime-avibactam | 0.06 to >256 | 0.25 | 2 |
Ceftazidime | 0.06 to >64 | 0.5 | >64 |
Amikacin | 1 to >64 | 1 | 8 |
Aztreonam | ≤0.03 to >64 | 0.12 | >64 |
Cefepime | 0.015 to >16 | 0.06 | >16 |
Ceftaroline | 0.03 to >256 | 0.25 | >256 |
Ceftriaxone | ≤0.015 to >32 | 0.25 | >32 |
Gentamicin | 0.25 to >16 | 0.5 | >16 |
Imipenem | 0.12 to 8 | 0.25 | 0.5 |
Levofloxacin | 0.03 to >8 | 0.06 | 8 |
Meropenem | 0.015 to >8 | 0.03 | 0.5 |
Piperacillin-tazobactam | 0.5 to >128 | 4 | >128 |
Tigecycline | 0.5 to 8 | 0.5 | 1 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | >8 |
Escherichia coli (549) | |||
Ceftazidime-avibactam | ≤0.008 to 4 | 0.06 | 0.12 |
Ceftazidime | ≤0.03 to >64 | 0.12 | 8 |
Amikacin | 0.5 to >64 | 2 | 4 |
Aztreonam | ≤0.03 to >64 | 0.06 | 16 |
Cefepime | ≤0.008 to >16 | 0.03 | 16 |
Ceftaroline | ≤0.008 to >256 | 0.06 | >256 |
Ceftriaxone | ≤0.015 to >32 | 0.06 | >32 |
Gentamicin | 0.25 to >16 | 0.5 | >16 |
Imipenem | 0.06 to 0.5 | 0.12 | 0.12 |
Levofloxacin | 0.008 to >8 | 0.03 | >8 |
Meropenem | 0.008 to 0.5 | 0.015 | 0.03 |
Piperacillin-tazobactam | ≤0.06 to >128 | 2 | 8 |
Tigecycline | 0.06 to 2 | 0.25 | 0.5 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | >8 |
Klebsiella oxytoca (32) | |||
Ceftazidime-avibactam | 0.03 to 0.25 | 0.06 | 0.12 |
Ceftazidime | ≤0.03 to 0.25 | 0.12 | 0.12 |
Amikacin | 0.5 to 4 | 1 | 1 |
Aztreonam | ≤0.03 to 1 | 0.06 | 0.25 |
Cefepime | 0.015 to 0.06 | 0.03 | 0.03 |
Ceftaroline | 0.03 to 0.5 | 0.12 | 0.25 |
Ceftriaxone | ≤0.015 to 0.12 | 0.03 | 0.06 |
Gentamicin | ≤0.12 to 1 | 0.25 | 0.5 |
Imipenem | 0.06 to 0.25 | 0.12 | 0.25 |
Levofloxacin | 0.03 to 1 | 0.06 | 0.06 |
Meropenem | 0.015 to 0.03 | 0.03 | 0.03 |
Piperacillin-tazobactam | 0.5 to 4 | 2 | 2 |
Tigecycline | 0.25 to 0.5 | 0.25 | 0.5 |
Trimethoprim-sulfamethoxazole | ≤0.25 to 0.5 | ≤0.25 | ≤0.25 |
Klebsiella pneumoniae (100) | |||
Ceftazidime-avibactam | ≤0.008 to >256 | 0.12 | 0.5 |
Ceftazidime | ≤0.03 to >64 | 0.12 | >64 |
Amikacin | 0.5 to >64 | 1 | 2 |
Aztreonam | ≤0.03 to >64 | ≤0.03 | >64 |
Cefepime | 0.015 to >16 | 0.03 | >16 |
Ceftaroline | 0.015 to >256 | 0.12 | >256 |
Ceftriaxone | ≤0.015 to >32 | 0.06 | >32 |
Gentamicin | ≤0.12 to >16 | 0.25 | >16 |
Imipenem | 0.06 to 16 | 0.12 | 0.25 |
Levofloxacin | 0.015 to >8 | 0.06 | >8 |
Meropenem | 0.015 to >8 | 0.03 | 0.12 |
Piperacillin-tazobactam | 0.5 to >128 | 2 | >128 |
Tigecycline | 0.25 to 4 | 0.5 | 2 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | >8 |
Proteus mirabilis (17) | |||
Ceftazidime-avibactam | 0.015 to 2 | 0.03 | 0.5 |
Ceftazidime | ≤0.03 to >64 | 0.06 | 32 |
Amikacin | 1 to 16 | 4 | 8 |
Aztreonam | ≤0.03 to 2 | ≤0.03 | 0.5 |
Cefepime | 0.03 to 2 | 0.06 | 1 |
Ceftaroline | 0.03 to >256 | 0.06 | 256 |
Ceftriaxone | ≤0.015 to >32 | ≤0.015 | >32 |
Gentamicin | 0.5 to >16 | 1 | >16 |
Imipenem | 0.12 to 4 | 1 | 4 |
Levofloxacin | 0.03 to >8 | 0.12 | >8 |
Meropenem | 0.03 to 0.12 | 0.06 | 0.12 |
Piperacillin-tazobactam | ≤0.06 to 16 | 0.25 | 4 |
Tigecycline | 2 to 8 | 4 | 4 |
Trimethoprim-sulfamethoxazole | ≤0.25 to >8 | ≤0.25 | >8 |
Pseudomonas aeruginosa (70) | |||
Ceftazidime-avibactam | 0.5 to 32 | 2 | 4 |
Ceftazidime | 1 to >64 | 2 | 8 |
Amikacin | ≤0.12 to >64 | 4 | 8 |
Cefepime | 0.5 to >16 | 2 | 8 |
Ceftriaxone | 4 to >32 | 32 | >32 |
Gentamicin | ≤0.12 to >16 | 1 | 2 |
Imipenem | 0.5 to 16 | 1 | 2 |
Levofloxacin | 0.03 to >8 | 0.5 | >8 |
Meropenem | 0.03 to >8 | 0.12 | 2 |
Piperacillin-tazobactam | 0.5 to >128 | 4 | 16 |
Total of 1,066 randomized patients. Some patients had more than one pathogen isolated. Multiple isolates of the same species from the same patient were counted only once using the isolate with the highest MIC to the study drug received. For bacteremic patients, multiple isolates of the same species from the same patient were counted only once using the isolate with the highest MIC to the study drug received across culture source (intra-abdominal site or blood).